Kenvue Tops Q4 Earnings Estimates, Advances Toward Kimberly-Clark Deal
KVUE reports solid Q4 results, with margin gains and broad-based global growth, while moving closer to its planned Kimberly-Clark acquisition.
Kenvue tops Q4 forecasts as Kimberly-Clark deal advances
Kenvue Inc (NYSE:KVUE) reported fourth quarter results that topped Wall Street expectations, while the consumer health company also outlined restructuring steps ahead of its planned combination with Kimberly-Clark. For Q4, Kenvue posted adjusted earnings per share of $0.27, beating analyst estimates of $0.22.
Kenvue Surges as Earnings Beat, Kimberly-Clark Merger Gains Steam
Kenvue (NYSE: KVUE) reported fourth-quarter results yesterday that exceeded analyst expectations, with adjusted EPS of $0.27 beating the FactSet estimate of $0.22 by 23%.
Kenvue (KVUE) Beats Q4 Earnings and Revenue Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.26 per share a year ago.
Kenvue to Cut 3.5% of Workforce Ahead of Kimberly-Clark Deal
The job cuts are part of a restructuring plan to optimize its operating model and drive operational efficiencies, the company said.
Kenvue beats quarterly estimates, announces job cuts amid Kimberly-Clark acquisition
Tylenol-maker Kenvue on Tuesday beat Wall Street estimates for fourth-quarter results and announced a global workforce reduction, as it proceeds toward a planned takeover by Kimberly-Clark.
Kimberly-Clark Posts Higher Profit Ahead of Kenvue Vote
Kimberly-Clark reported a higher profit in its latest quarter just days before shareholders vote on its plan to buy Kenvue, a deal designed to create a global health-and-wellness giant.
Kenvue: Worth Owning As Kimberly-Clark Deal Plays Out
Kimberly-Clark is acquiring Kenvue in a $48.7 billion cash-and-stock deal. I believe the deal is likely to close, and that Kenvue stock gives folks a decent way to buy Kimberly-Clark at a discount. There is still a solid deal spread here, and I think Kimberly-Clark is undervalued as well, offering additional upside once the deal closes.
US appeals court to weigh reviving cases over Tylenol and autism
A U.S. appeals court is expected to hear arguments on Monday from families seeking to revive their lawsuits over Tylenol, after the Trump administration publicly promoted their claims that the popular painkiller is linked to autism in children.
Judge to weigh if Texas AG can block Kenvue dividend over Tylenol
A Texas judge on Friday will consider state Attorney General Ken Paxton's bid to block Kenvue from paying a $398 million dividend to shareholders and from marketing Tylenol as safe for pregnant women.
Texas seeks to block Kenvue dividend amid Tylenol lawsuit
Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing risks to children from the use of Tylenol by pregnant women.
Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction
On Nov. 3rd, Wall Street rendered a swift and brutal verdict on Kimberly-Clark's NASDAQ: KMB transformative acquisition of Kenvue NYSE: KVUE. While Kenvue's shares climbed over 12%, Kimberly-Clark's stock price dropped more than 14% to a new 52-week low, wiping out approximately $5.8 billion in market value in a single trading session.
